Place · Level 3 · Intervention
Bariatric Surgery · the truth
重度肥胖唯一持续显著的干预 · SOS 10y 体重 -25% / 全因死亡 ↓29% · 不是懒人方案 · 改造解剖 + 改造肠道激素 · 终生随访 + 终生补充
Story path
- 1Procedures · expanded indicationsProcedures · expanded indications
- 2Mechanism · gut hormone remodelingMechanism · gut hormone remodeling
- 3Outcomes · strongest hard endpointsOutcomes · strongest hard endpoints
- 4Real costs · risks + lifelong supplementationReal costs · risks + lifelong supplementation
- 5Who should consider · who shouldn'tWho should consider · who shouldn't
Chapter 1
Procedures · expanded indications
Procedures · expanded indications
Bariatric surgery, more accurately called metabolic surgery today, is no longer just 'shrinking the stomach.' Three mainstream procedures plus historical ones:
1. Roux-en-Y gastric bypass (RYGB)
Creates a ~30 mL gastric pouch, bypasses the rest of the stomach + duodenum + proximal jejunum, then anastomoses the distal small bowel to the pouchFood bypasses ~100-150 cm of small bowel — both restrictive and anatomically altered absorptionHistoric 'gold standard', strongest and most durable weight loss, highest diabetes remission
2. Sleeve gastrectomy (SG)
Vertically resect ~80% of the stomach along the greater curvature, leaving a sleeve tube; no bypassSimplest anatomy, shortest operative time, fewer nutritional complications than RYGBSurpassed RYGB after 2013 to become the #1 procedure worldwide (~60% share)
3. Historical / niche procedures (rarely used)
Adjustable gastric band (Lap-Band): poor long-term outcomes, high revision rate, essentially abandonedBiliopancreatic diversion + duodenal switch (BPD/DS): greatest weight loss but severe nutritional complications, reserved for super-obesity (BMI ≥ 50) in expert centersSADI-S (single anastomosis duodenoileal bypass + SG): simplified BPD/DS, growing adoption
Indications expanded in 2022 (Eisenberg 2022 ASMBS/IFSO joint statement, replacing the 1991 NIH consensus):
BMI ≥ 35: recommended regardless of comorbiditiesBMI ≥ 30 + refractory T2D or metabolic syndrome: should be consideredAsian BMI ≥ 27.5 + comorbidity: consider (more visceral fat at same BMI, lower threshold)No more hard age cutoff — individualized (evidence growing in adolescents and older adults)Removes the rigid 'must try lifestyle for X months first' prerequisite (which often delays the optimal window)
Why the loosening: 30 years of follow-up data + modern laparoscopic 30-day mortality < 0.3% — surgical risk is now lower than the risk of untreated obesity itself. Current consensus: in the right patient, earlier is better.
1. Roux-en-Y gastric bypass (RYGB)
Creates a ~30 mL gastric pouch, bypasses the rest of the stomach + duodenum + proximal jejunum, then anastomoses the distal small bowel to the pouchFood bypasses ~100-150 cm of small bowel — both restrictive and anatomically altered absorptionHistoric 'gold standard', strongest and most durable weight loss, highest diabetes remission
2. Sleeve gastrectomy (SG)
Vertically resect ~80% of the stomach along the greater curvature, leaving a sleeve tube; no bypassSimplest anatomy, shortest operative time, fewer nutritional complications than RYGBSurpassed RYGB after 2013 to become the #1 procedure worldwide (~60% share)
3. Historical / niche procedures (rarely used)
Adjustable gastric band (Lap-Band): poor long-term outcomes, high revision rate, essentially abandonedBiliopancreatic diversion + duodenal switch (BPD/DS): greatest weight loss but severe nutritional complications, reserved for super-obesity (BMI ≥ 50) in expert centersSADI-S (single anastomosis duodenoileal bypass + SG): simplified BPD/DS, growing adoption
Indications expanded in 2022 (Eisenberg 2022 ASMBS/IFSO joint statement, replacing the 1991 NIH consensus):
BMI ≥ 35: recommended regardless of comorbiditiesBMI ≥ 30 + refractory T2D or metabolic syndrome: should be consideredAsian BMI ≥ 27.5 + comorbidity: consider (more visceral fat at same BMI, lower threshold)No more hard age cutoff — individualized (evidence growing in adolescents and older adults)Removes the rigid 'must try lifestyle for X months first' prerequisite (which often delays the optimal window)
Why the loosening: 30 years of follow-up data + modern laparoscopic 30-day mortality < 0.3% — surgical risk is now lower than the risk of untreated obesity itself. Current consensus: in the right patient, earlier is better.
Chapter 2
Mechanism · gut hormone remodeling
Mechanism · gut hormone remodeling
The core mechanism is not 'smaller stomach.' Pure restriction (e.g., the old Lap-Band) has long been shown to be ineffective with high recurrence. What actually works is deep remodeling of the gut hormone system after surgery — the key distinction from diet, exercise, or drugs.
Core hormonal changes (significant for both RYGB and SG, larger with RYGB):
Ghrelin (hunger hormone) ↓ profoundly: ghrelin is mainly produced by the gastric fundus; SG removes the fundus, RYGB excludes it from the food path → plasma ghrelin drops persistently. Patients experience genuinely reduced hunger, not 'willpower' (Cummings 2002 NEJM classic)glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. ↑ 5-10×: food rapidly reaches the distal small bowel → strong L-cell stimulation → massive GLP-1 release. Boosts satiety and powerfully drives insulin secretionPYY ↑: also from distal L cells, reinforces satiety signalingAltered bile acid metabolism: bile acid pathway remodeling → FXR / TGR5 activation → improved insulin sensitivity + microbiome modulationMicrobiome restructuring: Bacteroidetes ↑, Firmicutes ↓, more short-chain fatty acids
Why diabetes often remits before substantial weight loss:
Clinically observed repeatedly: within days after RYGB, before any visible thinning, glucose dramatically improves — some patients stop insulin before dischargeCause is exactly the hormonal changes above — especially the GLP-1 surge and gut-islet axis remodeling. This is what gave birth to the new term 'metabolic surgery', emphasizing that the essence is anatomical treatment of metabolic disease, not just weight lossSTAMPEDE / DSS RCTs confirm: surgical group's diabetes remission far exceeds drug controls, even at the same weight
Key contrast with diet alone:
Diet-induced weight loss → ghrelin rises (the body launches 'starvation defense'), leptin drops, REE drops → strong rebound (Sumithran 2011 NEJM, hormones still abnormal at 1 year)Bariatric surgery → ghrelin drops and stays down, GLP-1 + PYY rise and stay elevated → the body's 'set point' is actually shifted downThis difference explains why surgical weight loss lasts and dieting / drugs rebound when stopped
Limits of the mechanism:
Surgery doesn't eliminate all compensation: partial weight regain by year 5, some diabetes recurrenceBut rebound magnitude is far smaller and durability far longer than diet / drugsGLP-1 agonist drugs partially mimic the hormonal effect — but stopping them = rebound, while surgical anatomical change is permanent.
Core hormonal changes (significant for both RYGB and SG, larger with RYGB):
Ghrelin (hunger hormone) ↓ profoundly: ghrelin is mainly produced by the gastric fundus; SG removes the fundus, RYGB excludes it from the food path → plasma ghrelin drops persistently. Patients experience genuinely reduced hunger, not 'willpower' (Cummings 2002 NEJM classic)glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. ↑ 5-10×: food rapidly reaches the distal small bowel → strong L-cell stimulation → massive GLP-1 release. Boosts satiety and powerfully drives insulin secretionPYY ↑: also from distal L cells, reinforces satiety signalingAltered bile acid metabolism: bile acid pathway remodeling → FXR / TGR5 activation → improved insulin sensitivity + microbiome modulationMicrobiome restructuring: Bacteroidetes ↑, Firmicutes ↓, more short-chain fatty acids
Why diabetes often remits before substantial weight loss:
Clinically observed repeatedly: within days after RYGB, before any visible thinning, glucose dramatically improves — some patients stop insulin before dischargeCause is exactly the hormonal changes above — especially the GLP-1 surge and gut-islet axis remodeling. This is what gave birth to the new term 'metabolic surgery', emphasizing that the essence is anatomical treatment of metabolic disease, not just weight lossSTAMPEDE / DSS RCTs confirm: surgical group's diabetes remission far exceeds drug controls, even at the same weight
Key contrast with diet alone:
Diet-induced weight loss → ghrelin rises (the body launches 'starvation defense'), leptin drops, REE drops → strong rebound (Sumithran 2011 NEJM, hormones still abnormal at 1 year)Bariatric surgery → ghrelin drops and stays down, GLP-1 + PYY rise and stay elevated → the body's 'set point' is actually shifted downThis difference explains why surgical weight loss lasts and dieting / drugs rebound when stopped
Limits of the mechanism:
Surgery doesn't eliminate all compensation: partial weight regain by year 5, some diabetes recurrenceBut rebound magnitude is far smaller and durability far longer than diet / drugsGLP-1 agonist drugs partially mimic the hormonal effect — but stopping them = rebound, while surgical anatomical change is permanent.
Chapter 3
Outcomes · strongest hard endpoints
Outcomes · strongest hard endpoints
SOS Trial (Swedish Obese Subjects, Sjöström 2007 NEJM): the most important long-term prospective cohort in weight management.
Design:
Sweden, 4047 severely obese patients (BMI ≥ 34 men / ≥ 38 women), enrolled 1987-20012010 surgical vs 2037 matched conventional-care controls, matched on 18 baseline variablesMean follow-up 10.9 years (extended to 20+)Note: non-randomized (impossible to randomize severe obesity to long-term control ethically), but rigorous matching — highest evidence available
Hard endpoints:
Weight: surgical group -23% (10y), -18% (20y); controls ±2%All-cause mortality: surgical ↓ 29% (HR 0.71)T2D incidence: surgical ↓ 80% (HR 0.17, 2y follow-up)Cardiovascular events (fatal + nonfatal MI/stroke): surgical ↓ 33% (HR 0.67)Cancer incidence (women): ↓ 42%Microvascular complications: ↓ 56%
This is a uniquely strong evidence level in weight-loss history: no diet / exercise / drug intervention has demonstrated this magnitude of reduction in all-cause mortality and cardiovascular hard endpoints.
Diabetes remission RCTs (STAMPEDE 5y, DSS 10y, Mingrone et al.):
Surgical group complete diabetes remission 35-50% (HbA1c < 6%, no glucose-lowering drugs)Intensive medical therapy remission 5-10%Even after partial relapse, surgical group's glucose control + drug burden remained markedly better
Vs glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. agonists (STEP 1, Wilding 2021):
semaglutide 2.4 mg weekly × 68 weeks → weight -14.9%tirzepatide (SURMOUNT-1) × 72 weeks → -20.9%Bariatric surgery 12-24 months → -25-35%, still -18 to -25% at 10 yearsDrugs rebound on discontinuation (STEP 4: 2/3 regained within a year off-drug); surgical loss is durableCurrent guidance: drugs ≈ first-line (especially BMI 30-40), surgery ≈ stronger tool for severer obesity or severe metabolic disease; not mutually exclusive — a ladder
SOS also reminds:
Not all subgroups benefit equally — those with worse baseline metabolic disease benefit mostLong-term follow-up also exposed alcohol misuse / suicide risk / nutritional deficiency as real costs (next scene).
Design:
Sweden, 4047 severely obese patients (BMI ≥ 34 men / ≥ 38 women), enrolled 1987-20012010 surgical vs 2037 matched conventional-care controls, matched on 18 baseline variablesMean follow-up 10.9 years (extended to 20+)Note: non-randomized (impossible to randomize severe obesity to long-term control ethically), but rigorous matching — highest evidence available
Hard endpoints:
Weight: surgical group -23% (10y), -18% (20y); controls ±2%All-cause mortality: surgical ↓ 29% (HR 0.71)T2D incidence: surgical ↓ 80% (HR 0.17, 2y follow-up)Cardiovascular events (fatal + nonfatal MI/stroke): surgical ↓ 33% (HR 0.67)Cancer incidence (women): ↓ 42%Microvascular complications: ↓ 56%
This is a uniquely strong evidence level in weight-loss history: no diet / exercise / drug intervention has demonstrated this magnitude of reduction in all-cause mortality and cardiovascular hard endpoints.
Diabetes remission RCTs (STAMPEDE 5y, DSS 10y, Mingrone et al.):
Surgical group complete diabetes remission 35-50% (HbA1c < 6%, no glucose-lowering drugs)Intensive medical therapy remission 5-10%Even after partial relapse, surgical group's glucose control + drug burden remained markedly better
Vs glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. agonists (STEP 1, Wilding 2021):
semaglutide 2.4 mg weekly × 68 weeks → weight -14.9%tirzepatide (SURMOUNT-1) × 72 weeks → -20.9%Bariatric surgery 12-24 months → -25-35%, still -18 to -25% at 10 yearsDrugs rebound on discontinuation (STEP 4: 2/3 regained within a year off-drug); surgical loss is durableCurrent guidance: drugs ≈ first-line (especially BMI 30-40), surgery ≈ stronger tool for severer obesity or severe metabolic disease; not mutually exclusive — a ladder
SOS also reminds:
Not all subgroups benefit equally — those with worse baseline metabolic disease benefit mostLong-term follow-up also exposed alcohol misuse / suicide risk / nutritional deficiency as real costs (next scene).
Chapter 4
Real costs · risks + lifelong supplementation
Real costs · risks + lifelong supplementation
Bariatric surgery is not 'lying down to lose weight.' It is a major intervention with explicit costs. Listed honestly:
1. Surgical risk itself (modern laparoscopic, high-volume centers):
30-day mortality 0.1-0.3% (slightly below cholecystectomy), not zeroMajor complications 5-15%: anastomotic leak (RYGB 1-3%, most dangerous), bleeding, DVT/PE, stenosis at incision/anastomosis, internal hernia (RYGB late 5-10%)Reoperation rate: 5-10% within 5 years for revision or complication managementMortality strongly correlates with center volume — non-high-volume centers carry markedly higher risk
2. Lifelong nutritional deficiencies:
Vitamin B12 deficiency: RYGB bypasses gastric acid + intrinsic factor sites → lifelong B12 supplementation required (oral 1000 µg/day or injection). Untreated → neuropathy, possibly irreversibleIron deficiency: duodenum is the primary iron-absorption site, RYGB bypasses it → iron-deficiency anemia common (especially women), lifelong ironCalcium + vitamin D deficiency → bone loss: BMD drops 5-10% in 5y post-RYGB, hip fracture risk rises; lifelong calcium 1200-1500 mg/day + vit D 3000 IU/dayVitamins A / E / K / thiamine (B1): BPD/DS highest risk, RYGB moderate. Acute thiamine deficiency → Wernicke encephalopathy (especially with post-op intractable vomiting)Inadequate protein intake: capacity limited → must hit ≥ 60-80 g protein/day; failure → sarcopenia + hair loss
3. Dumping syndrome (more in RYGB):
Early (15-30 min after eating): high-sugar/carb rapidly enters small bowel → osmotic fluid shift → palpitations / sweating / dizziness / abdominal pain / diarrheaLate (1-3 hours): reactive hypoglycemia, severe cases fall or syncopePatients must relearn eating cadence (small frequent meals, low sugar, protein first, no liquids with meals)
4. GERD worsening (more in SG):
~15-30% of SG patients develop new or worsened reflux; some require conversion to RYGBRYGB actually improves GERD
5. Psychological / behavioral risks:
Alcohol use disorder (AUD) risk ↑: SOS follow-up + multiple cohorts show post-RYGB AUD incidence ~2× pre-op (faster alcohol absorption + 'addiction transfer' hypothesis)Suicide / self-harm risk ↑: several studies show higher self-harm rates than general obese population; mechanism not fully understood (body image / relationships / metabolic biochemistry hypotheses)Relationship upheaval: dramatic weight change often comes with marital / occupational / self-identity restructuring; divorce rates riseTherefore preoperative psychological assessment + lifelong psychological follow-up are mandatory in international guidelines
6. Weight regain:
At 5-10 years some patients regain ~20-25% of lost weight (net loss from peak -35% to -20-25%)But still far better than drugs or lifestyle, net benefit persistsRegain magnitude correlates strongly with diet habits / exercise / psychological state / adjunctive glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. use
7. Lifelong follow-up:
Year 1: every 3 months, including nutritional labs + psychological evaluationThereafter annually for life: B12 / iron / calcium / vit D / parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. / protein / BMD (every 2 years)If you are unwilling to accept this lifelong follow-up, do not have the surgery.
1. Surgical risk itself (modern laparoscopic, high-volume centers):
30-day mortality 0.1-0.3% (slightly below cholecystectomy), not zeroMajor complications 5-15%: anastomotic leak (RYGB 1-3%, most dangerous), bleeding, DVT/PE, stenosis at incision/anastomosis, internal hernia (RYGB late 5-10%)Reoperation rate: 5-10% within 5 years for revision or complication managementMortality strongly correlates with center volume — non-high-volume centers carry markedly higher risk
2. Lifelong nutritional deficiencies:
Vitamin B12 deficiency: RYGB bypasses gastric acid + intrinsic factor sites → lifelong B12 supplementation required (oral 1000 µg/day or injection). Untreated → neuropathy, possibly irreversibleIron deficiency: duodenum is the primary iron-absorption site, RYGB bypasses it → iron-deficiency anemia common (especially women), lifelong ironCalcium + vitamin D deficiency → bone loss: BMD drops 5-10% in 5y post-RYGB, hip fracture risk rises; lifelong calcium 1200-1500 mg/day + vit D 3000 IU/dayVitamins A / E / K / thiamine (B1): BPD/DS highest risk, RYGB moderate. Acute thiamine deficiency → Wernicke encephalopathy (especially with post-op intractable vomiting)Inadequate protein intake: capacity limited → must hit ≥ 60-80 g protein/day; failure → sarcopenia + hair loss
3. Dumping syndrome (more in RYGB):
Early (15-30 min after eating): high-sugar/carb rapidly enters small bowel → osmotic fluid shift → palpitations / sweating / dizziness / abdominal pain / diarrheaLate (1-3 hours): reactive hypoglycemia, severe cases fall or syncopePatients must relearn eating cadence (small frequent meals, low sugar, protein first, no liquids with meals)
4. GERD worsening (more in SG):
~15-30% of SG patients develop new or worsened reflux; some require conversion to RYGBRYGB actually improves GERD
5. Psychological / behavioral risks:
Alcohol use disorder (AUD) risk ↑: SOS follow-up + multiple cohorts show post-RYGB AUD incidence ~2× pre-op (faster alcohol absorption + 'addiction transfer' hypothesis)Suicide / self-harm risk ↑: several studies show higher self-harm rates than general obese population; mechanism not fully understood (body image / relationships / metabolic biochemistry hypotheses)Relationship upheaval: dramatic weight change often comes with marital / occupational / self-identity restructuring; divorce rates riseTherefore preoperative psychological assessment + lifelong psychological follow-up are mandatory in international guidelines
6. Weight regain:
At 5-10 years some patients regain ~20-25% of lost weight (net loss from peak -35% to -20-25%)But still far better than drugs or lifestyle, net benefit persistsRegain magnitude correlates strongly with diet habits / exercise / psychological state / adjunctive glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. use
7. Lifelong follow-up:
Year 1: every 3 months, including nutritional labs + psychological evaluationThereafter annually for life: B12 / iron / calcium / vit D / parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. / protein / BMD (every 2 years)If you are unwilling to accept this lifelong follow-up, do not have the surgery.
Chapter 5
Who should consider · who shouldn't
Who should consider · who shouldn't
Place surgery on the 'intervention ladder' at the strongest end — not the first option, not the last, but the most effective tool for a specific population.
Should consider surgery (multiple of):
BMI ≥ 40 (no comorbidities) or BMI ≥ 35 + severe comorbidity (T2D / hypertension / OSA / MASH / severe joint burden)BMI ≥ 30 + refractory T2D (HbA1c uncontrolled ≥ 6 months on appropriate drugs) — newly expanded by 2022 ASMBSAsian BMI ≥ 27.5 + severe metabolic comorbidity — surgery should be seriously discussedHas systematically tried structured lifestyle + drugs (including GLP-1 if economically and clinically feasible) without sustained meaningful effectPsychological assessment stable: understands the surgical implication, can commit to lifelong follow-up + lifelong nutritional supplementationUnderstands surgery is not the finish line: diet change / exercise / psychological work are companions, not optionalSupport system in place: family / financial / medical access can sustain 5-10 years
Should NOT have surgery (absolute or relative contraindications):
Treating surgery as 'quick cosmetics' — purely appearance-driven, no understanding of long-term cost → strongly discouragedUnwilling to do lifelong nutritional supplementation and follow-up — failing to take B12 / iron / calcium / vit D leads to irreversible neuropathy and fracturesActive substance use disorder (alcohol / opioids / benzodiazepines) — surgery amplifies alcohol-related risks; stabilize firstUncontrolled severe mental illness (active psychosis, severe untreated depression, eating disorder) — treat and stabilize firstPregnancy planned within 12-18 months — rapid post-op weight change is unsafe; nutritional deficiency affects fetusLimited life expectancy from other severe disease — benefit window too shortCannot adhere to post-op dietary restructuring — technical failure highly likely
A realistic frame for the hesitant:
It's not 'no surgery = status quo': untreated severe obesity has enormous long-term cost (T2D / cardiovascular / cancer / joint / lifespan shortened 6-10 years; global-bmi-mort 2016 Lancet large meta)Compare 'surgical risk + lifelong supplementation + psychological adjustment' against 'untreated severe obesity + accumulating comorbidities + shortened lifespan'For those truly meeting indications, current evidence consistently shows earlier is betterThose not meeting indications (BMI 25-30 wanting to lose 5 kg, cosmetic intent) should not — risk-benefit doesn't hold
Relationship with the rung below (glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar.):
Many patients' current path: lifestyle → GLP-1 (months to years) → reassess; for most, GLP-1 is enoughIf GLP-1 insufficient (loss < 10% and comorbidities unimproved), or rebound on discontinuation is unsustainable → escalate to surgical evaluationSome use low-dose GLP-1 post-surgery to manage partial regain — not mutually exclusive
Atlas connections:
weight-management-foundations (energy balance / weight regulation basics)leptin-set-point (why dieting rebounds, why surgery can shift the set point down)glp1-agonists-deep (the rung below)type-2-diabetes + metabolic-syndrome (main comorbidities and benefit scenarios)nafld (MASLD co-occurs with obesity; ≥ 10% weight loss is also first-line treatment)
Should consider surgery (multiple of):
BMI ≥ 40 (no comorbidities) or BMI ≥ 35 + severe comorbidity (T2D / hypertension / OSA / MASH / severe joint burden)BMI ≥ 30 + refractory T2D (HbA1c uncontrolled ≥ 6 months on appropriate drugs) — newly expanded by 2022 ASMBSAsian BMI ≥ 27.5 + severe metabolic comorbidity — surgery should be seriously discussedHas systematically tried structured lifestyle + drugs (including GLP-1 if economically and clinically feasible) without sustained meaningful effectPsychological assessment stable: understands the surgical implication, can commit to lifelong follow-up + lifelong nutritional supplementationUnderstands surgery is not the finish line: diet change / exercise / psychological work are companions, not optionalSupport system in place: family / financial / medical access can sustain 5-10 years
Should NOT have surgery (absolute or relative contraindications):
Treating surgery as 'quick cosmetics' — purely appearance-driven, no understanding of long-term cost → strongly discouragedUnwilling to do lifelong nutritional supplementation and follow-up — failing to take B12 / iron / calcium / vit D leads to irreversible neuropathy and fracturesActive substance use disorder (alcohol / opioids / benzodiazepines) — surgery amplifies alcohol-related risks; stabilize firstUncontrolled severe mental illness (active psychosis, severe untreated depression, eating disorder) — treat and stabilize firstPregnancy planned within 12-18 months — rapid post-op weight change is unsafe; nutritional deficiency affects fetusLimited life expectancy from other severe disease — benefit window too shortCannot adhere to post-op dietary restructuring — technical failure highly likely
A realistic frame for the hesitant:
It's not 'no surgery = status quo': untreated severe obesity has enormous long-term cost (T2D / cardiovascular / cancer / joint / lifespan shortened 6-10 years; global-bmi-mort 2016 Lancet large meta)Compare 'surgical risk + lifelong supplementation + psychological adjustment' against 'untreated severe obesity + accumulating comorbidities + shortened lifespan'For those truly meeting indications, current evidence consistently shows earlier is betterThose not meeting indications (BMI 25-30 wanting to lose 5 kg, cosmetic intent) should not — risk-benefit doesn't hold
Relationship with the rung below (glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar.):
Many patients' current path: lifestyle → GLP-1 (months to years) → reassess; for most, GLP-1 is enoughIf GLP-1 insufficient (loss < 10% and comorbidities unimproved), or rebound on discontinuation is unsustainable → escalate to surgical evaluationSome use low-dose GLP-1 post-surgery to manage partial regain — not mutually exclusive
Atlas connections:
weight-management-foundations (energy balance / weight regulation basics)leptin-set-point (why dieting rebounds, why surgery can shift the set point down)glp1-agonists-deep (the rung below)type-2-diabetes + metabolic-syndrome (main comorbidities and benefit scenarios)nafld (MASLD co-occurs with obesity; ≥ 10% weight loss is also first-line treatment)